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Since 1996
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Moved to this campus in 2004
National Institute of Cancer Research 
Institute of Cellular and System Medicine 
Division of Aging-Related Musculoskeletal Diseases 
Division of Cardiovascular and Metabolism Medicine 
Division of Regenerative Medicine 
Institute of Population Sciences 
Center for Health Policy Research & Development 
Division of Biostatistics and Bioinformatics 
Research Programs
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Division of Gerontology Research 
Division of Mental Health & Substance Abuse Research 
Institute of Biotechnology & Pharmaceutical Research 
National Institute of Infectious Diseases and Vaccinology 
Division of Environmental Health & Occupational Medicine 
Division of Medical Engineering Research 
Division of Molecular & Genomic Medicine 
Center for Nanomedicine Research 
Institution Objectives and manpower
Improve the health and well-being 
of Taiwanese
Enhance the quality of biomedical 
research and medical care
Develop medical and 
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pharmaceutical technology
Train and cultivate biomedical 
researchers
Promote health policy research and 
implementation
 Total: over 1600




NIIDV Organization & Structure
Effective, May, 2011
National Institute of Infectious Diseases 
and Vaccinology ( NIIDV )
Vaccine  R&D Center
Division of Infectious 
Diseases
PathogenicSurveillance Clinic Policy
13+58 12+125 ( 91 )
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• Antibiotic resistance, microbial genomics and 
infection control Advocacy
• Tuberculosis research and novel BCG/ TB 
vaccine development
• Emerging virus infections and vaccine 
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development
• Tumor viruses and therapeutic development
• Novel vaccine technology and bioproduct 
development
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Flu Vaccine Enhance national Bio-security and 
capability to produce vaccine under 
emergency and /or pandemic disease
DOH Regular 
Funding/ Industry
Enterovirus : EV71 (B4/C4)
Category 3:
Developing  
Meningoccoccal Group B 
Vaccine
Complete product development up 
to phase 2 clinical trial and then 
MOEA/ Industry/ 
DOH
Pipelines of NHRI Vaccine Center
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technology and product transfer
Meningococcal group B using 
lipoprotein technology is going to 













Vaccine platform technology 
development and novel vaccine R&D 
to assist, reduce the cost and 
timelines and enhance the product 
pipelines in Taiwan vaccine industry





Vaccine R&D : NHRI cGMP Pilot Plant
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Source from: N Engl J Med; pp. 2540~2543, 2008
Our choice
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Process Development in VRDC
2.2L 7.5L 30 L 150 L
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(a) Confluent microcarriers (b) Cytopathic effect   (c) Purfied Virus particle .
(a) (b) (c)
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Hyclone 50L/200L SUB Sartorius 70L Cultibag STR
Downstream Purification using Continuous 
ultracentrifuge
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*The use of DE: diatomaceous earth (硅藻土) had 
significant effect on DNA  and protein removal
(DE) (DE) (DE) (DE) (PP) (DE+PP)
Depth filter test on large scale
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POROS HQ20 HA dsDNA
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1: After Concentration















5: After Gel filtration
6: After Anion-exchange




























XK 16/40 UV280 Hiscale 50/40 UV 280












































XK 16/40 UV280 Hiscale 50/40 UV 280
XK 16/40 dsDNA Hiscale 50/40 dsDNA












SRD (ug/ml) 76.1 32.32 33.18 24.67 29.81
BCA (µg/ml) NA 68.06 69.21 45.56 41.19
$ 282 $ 265
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µg/dose NA 30.9 31.5 28.5 20.6
residue DNA
(ng/ml)
8.334 10.926 14.006 3.094 2.6
residue DNA 
(ng/dose)
1.6 5.0 6.4 1.9 1.3
Predicted Doses
(based on 4L harvet)





DNA variation from different culturing system
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 NBS 33 run of 5L SEC 5040001:10_UV1_280nm  NBS 33 run of 5L SEC 5040001:10_UV2_260nm  NBS 33 run of 5L SEC 5040001:10_Cond
 NBS 33 run of 5L SEC 5040001:10_Fractions  NBS 33 run of 5L SEC 5040001:10_Inject  NBS 33 run of 5L SEC 5040001:10_Protein (ug per ml)
 NBS 33 run of 5L SEC 5040001:10_dsDNA by Qbit (ng per ml)  NBS 33 run of 5L SEC 5040001:10_HA unit per 50ul





  0 100 200 300 400 500 600 700 ml
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Opti-pro
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Sub 3
 column test 13 SEC 5040001:10_UV1_280nm  column test 13 SEC 5040001:10_UV2_260nm  column test 13 SEC 5040001:10_Cond
 column test 13 SEC 5040001:10_Fractions  column test 13 SEC 5040001:10_HA unit per 50ul  column test 13 SEC 5040001:10_dsDNA by Q bit
 column test 13 SEC 5040001:10_Protein by coomassie plus
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Plus_MDCK
Summary
• The use of diatomaceous earth dad significant effect on DNA  
and protein removal, but mechanism is not clear how DE 
absorbed the impurities
• Low DNA content can be achieved by SEC and AEX columns, 
thus no addition of DNase is needed
• The use of LC chromatography showed a similar results that 
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compared to ultracentrifuge technology
• Variations from Upstream harvest could affect heavily on 
downstream purification




• Department of Health
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Bioprocess team
• Center for Drug 
Evaluation
• Science Advisory 
Board
